Search
Stiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigationalStiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs. … [A250825] However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs
Laropiprant
go.drugbank.com/drugs/DB11629ApprovedWithdrawnLaropiprant is an ingredient in the EMA-withdrawn product Pelzont.
Sucralose
go.drugbank.com/drugs/DB15049InvestigationalSucralose is an artificial sweetener used as a sugar substitute.
Categories: Compounds used in a research, industrial, or household settingTicarcillin
go.drugbank.com/drugs/DB01607ApprovedVet approvedWithdrawnAn antibiotic derived from penicillin similar to carbenicillin in action.
Cinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia.
Paromomycin
go.drugbank.com/drugs/DB01421ApprovedInvestigationalAn oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Synonyms: Monomycin A, Zygomycin A1Abemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexVotucalis
go.drugbank.com/drugs/DB05032InvestigationalIt is a topically delivered small protein that acts as an anti-inflammatory agent.
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalBRAF V600E or V600K mutation, as detected by an FDA-approved test. … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.
MBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.